Our innovative biomarker panel will enable the accurate diagnosis of cancer patients through scalable, PCR-based assays that deliver industry-leading
95% accuracy rate in tissue samples and over 70% sensitivity in early patient blood samples.
Epi One scientists have a deep understanding of how epigenetic mechanisms regulate gene activity and influence tumorigenesis and disease progression. By integrating cutting-edge, high-throughput technologies with our proprietary computational algorithms, we leverage fewer than 10 genes to address a broad range of clinical challenges. This approach enables the identification of highly precise biomarkers for multi-cancer early detection, minimal residual disease (MRD), tumor-of-origin determination, patient triage, and prognosis.
For certain tumor types, such as prostate cancer, biopsy, the current gold standard for cancer diagnosis, has a high false-negative rate. For others, including pancreatic cancer, reliable methods for early detection are still lacking.
Epi One’s cancer diagnostic platform addresses these gaps by delivering accurate results within seven hours. Our goal is to make this test widely accessible at a cost of less than 1/3 of whole genome sequencing per patient, initially offering highly accurate biomarkers for prostate cancer, with plans to expand into lung, pancreatic, and MCED.
Our assay is highly scalable, and is simpler, faster, cheaper than sequencing-based technology.
Highly
Accurate
Simple
PCR test
<10 Biomarkers
per test
<1/3 of sequencing cost
7 Hour
Turnaround
Interested in Learning More?